Objectives: This study was used to demonstrate the feasibility of haplotype-based 23 noninvasive prenatal diagnosis for Hemophilia A. 24 Methods: Two families affected by Hemophilia A participated in our study. Maternal 25 haplotypes associated with pathogenic mutation was built using targeted region genotypes of 26 mother and the proband. Combined with maternal pathogenic haplotype, a Hidden Markov 27 Model was constructed to deduce fetal haplotype using high-coverage targeted sequencing of 28 maternal plasma. The presence of pathogenic haplotype in male indicated affected fetus, in 29 female indicated carrier. Prenatal diagnosis was confirmed with amniocentesis by long 30 distance PCR. 31 Results: The haplotype-based noninvasive prenatal diagnosis was successfully performed in 32 Hemophilia A. One fetus was identified to be normal, another fetus was identified as carrier, 33 and the results were confirmed by amniocentesis . 34 Conclusion: Our research demonstrated the feasibility of noninvasive prenatal diagnosis for 35 Hemophilia A by haplotype-based approach.
Introduction
Hemophilia A (HA) is one of the most common X-linked recessive inherited bleeding 38 disorder with a incidence of approximately 1/5,000 in males 1 . HA was caused by genetic 39 mutation of F8 gene, resulting in deficiency of coagulation factor factor VIII in plasma levels. 40 The clinically mainifesting was spontaneous or traumatic bleeding in several organs. Prenatal 41 diagnosis is important for HA families because of lacking in effective curing method. But the 42 invasive prenatal diagnosis may led a small risk of miscarriage and infection 2 . The discovery 43 of cell free fetal DNA (cff-DNA) in maternal plasma makes noninvasive prenatal diagnosis 44 (NIPD) possible 3 . The intron 22 inversion in F8 gene accouts for approximately 45% of 45 severe HA patients. Because of the vast background of maternal DNA 4 and technical 46 obstacles in determining the inversion breakpoint in plasma, the direct detection is 47 impracticable. The haplotype-based method could potentially solve the problem through 48 analyzing the mutation-linked polymorphism sites 5 . This was the few use of NIPD for HA by 49 haplotype-based approach to demonstrate our approach to be an affordable strategy for 50 clinical feasibility of NIPD of X-linked disorders. 51 52
Materials and Methods

53
HA cases recruitment and clinical information 54 Two families F01-F02 diagnosed with HA were recruited including two pregnant women, 55 their spouses, and their brother affected by HA. The causative mutation in the brothers and 56 the pregnant women were previously identified to be intron 22 inversion in F8 gene by long 57 distance PCR (LD-PCR). Genetic counseling were given to the families and the parents 58 decided to take our noninvasive prenatal test. All participants signed the informed consent. 59 The ethics committee of The First Affiliated Hospital of Guangzhou Medical University 60 approved this study. The 5 mL blood samples obtained from each of family members 61 including mother, father and proband were transported to BGI-Tianjin. Maternal plasma was 62 separated using double-centrifugation method and stored frozen in time. Amnioticfluid was 63 obtained through amniocentesis for routine prenatal diagnosis. Invasive prenatal diagnosis 64 and NIPD were performed in a double-blind manner by two independent investigators.
65
Library preparation and targeted sequencing 66 In this study we used haplotype-based noninvasive prenatal testing of HA using a 110.08 67 kb SeqCap kit (Roche) including F8 gene coding region and 445 surrounding highly 68 heterozygous SNPs (Minor Allele Frequency, MAF=0.3-0.5) distributed within 1Mb 69 chromosome X region( Figure 1 ).Inclusion of 10.37kb chromosome Y-specific region 70 facilitates the simultaneous determination of fetal gender. 71 Genomic DNA (gDNA) and cell free DNA was extracted from blood or umbilical cord 72 blood and maternal plasma using QIAamp DNA Mini kit (Qiagen) and QIAamp Circulating 73 Nucleic Acid Kit (Qiagen), respectively. The library was prepared according to our mature 74 protocal. The libraries of gDNA and cell free DNA were pooled into one and then captured 75 using our customized probe, respectively. Using BWA software, the sequencing reads were 76 aligned to the human reference genome (hg19). SNP calling was performed using GATK 77 software. 79 The mean depth of target region in Y chromosome was utilized to determine the fetal sex. 80 If the fetus is female, the depth of Y chromosome region would be extremely low, resulting 81 from short non-specific region reads could be mapped to Y chromosome specific region. 82 The fetal DNA concentration in maternal plasma fraction was calculated by taking 83 advantage of SNP sets with different parental homozygosity according to the formula: Haplotype-based noninvasive prenatal diagnosis of F8 gene 89 A noninvasive haplotype-based linkage analysis method as previous described 6 was used 90 to determine fetal haplotype using the SNP information flanking the 1M and coding region of 91 F8 gene of proband and parents . We defined haplotype 0 (Hap0) as the pathogenic haplotype 92 and haplotype 1 (Hap1) as the wildtype haplotype. Because the candidate Hap0 was inherited 93 from maternal chromosome X and we directly phased the maternal haplotypes of F8 gene. . 94 Based on maternal haplotype and SNP representation in the plasma, an HMM was constructed. 95 We chose the SNP sets which were heterozygous in mother but homozygous in father to 96 acquire the maternal inheritance. The fetal DNA fraction and sequencing error rate were 97 utilized to determine the maternal haplotypes inheritance in the fetus. The probability of each 98 state of maternal inheritance was calculated for each SNP marker in the maternal plasma. The 99 fetal haplotype was deduced using Viterbi algorithm used to decode the most hidden states. 
Determination of fetal gender and DNA fraction
Results
107
Sequencing data 108 For maternal plasma , we obtained a mean 41.35 million data mapped to target region 109 with a mean depth of 375.61x and 99.48% coverage more than 20 reads. A mean depth of 110 151.08x was obtained in genomic DNA of pregnant woman, her brother and her spouse, 111 respectively and the 20x coverage was 97.93% (Table 1) . The data satisfied subsequent 112 analysis.
113
Estimation of fetal gender and DNA fraction 114 The mean depth and 20x coverage mapped to chromosome Y in F01 plasma was 26.5x 115 and 42.59%, respectively. The fetus of F01 was inferred to be male. However, no reads was 116 mapped to target region of chromosome Y, the fetus of F02 was determined to be female. The 117 fetal DNA fraction of F01 and F02 was 11.09% and 9.37%, respectively.
118
Haplotype-based noninvasive prenatal diagnosis 119 The maternal haplotype could be constructed based on these SNPs. The number of 120 informative phased SNPs used for NIPD for F01 and F02 was 144 and 49, respectively. In 121 F01, the number of SNPs (Table 2, Figure 2 ) supported fetus inherited maternal wild 122 haplotype (Hap1) was 144, while none supported the pathogenic haplotype (Hap0). The fetus 123 could be subsequently predicted to be unaffected with HA considering the fetal male gender. 124 In F02, the number of SNPs ( Prenatal diagnosis performed by LD-PCR on the F01 was proved to be unaffected fetus 129 with HA ( Figure 3A ).The fetus of F02 was diagnosed as carrier with HA ( Figure 3B ). Even though NIPD on HA has a lot of advantages compared with the invasive methods, 175 but the accuracy needs to be further improved before clinical application. As accuracy 176 increases and cost reduce, we hypothesized that NIPD will be used as an alternative for 177 pregnant women who are likely to have fetuses with HA and other x-linked diseases in the 178 future, faster and easier.
